Analytic Investors’s Pacific Biosciences PACB Stock Holding History

Analytic Investors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-50,597	Closed	-$356K	–	657
2016 Q2	$356K	Buy	+50,597	New	+$462K	﹤0.01%	509
2016 Q1	–	Sell	-34,614	Closed	-$454K	–	666
2015 Q4	$454K	Buy	+34,614	New	+$311K	0.01%	512

Other funds holding PACB

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Analytic Investors's PACB Position: Q3 2016 in Review

Analytic Investors sold out of Pacific Biosciences (PACB) in Q3 2016, closing a stake of 50,597 shares — an estimated $356K sold.

Analytic Investors first reported a position in PACB in Q4 2015 and held it in 2 quarters. The position peaked at $454K in Q4 2015. 128 funds tracked by Wall St. Rank hold PACB as of Q3 2016.

Analytic Investors reported no remaining Pacific Biosciences position as of Q3 2016 after selling out during the quarter.
Analytic Investors sold 50,597 Pacific Biosciences shares in Q3 2016, an estimated $356K.
Analytic Investors first reported a position in Pacific Biosciences in Q4 2015 and held it in 2 quarters.
Analytic Investors's Pacific Biosciences position peaked at $454K in Q4 2015.
128 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.